M

Myriad Genetics
D

MYGN

3.92000
USD
-0.02
(-0.38%)
مغلق
حجم التداول
58,743
الربح لكل سهم
-0
العائد الربحي
-
P/E
-4
حجم السوق
361,335,341
أصول ذات صلة
ABT
ABT
-0.240
(-0.18%)
131.240 USD
DGX
DGX
1.620
(0.96%)
171.200 USD
E
EXAS
0.490
(0.87%)
56.980 USD
HOLX
HOLX
-0.220
(-0.40%)
54.260 USD
LH
LH
0.680
(0.28%)
242.510 USD
TMO
TMO
-6.77
(-1.69%)
393.52 USD
المزيد
الأخبار المقالات

العنوان: Myriad Genetics

القطاع: Healthcare
الصناعة: Diagnostics & Research
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.